Rafiq Hasan's Colleagues at Complement Therapeutics
Rafiq Hasan's Contact Details
United Kingdom
Complement Therapeutics
Rafiq Hasan's Company Details
Complement Therapeutics (CTx) is an early stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases as well as developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform. The Company is a spin out from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade whilst the CPM platform employs a unique methodology to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease. Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.